SequelSEC

Citius Pharmaceuticals, Inc. CTXR

Pharmaceutical Preparations · CIK 0001506251 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$1.49M
Fiscal year ended 2026-06-30
Operating income
-$11.73M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Citius Pharmaceuticals, Inc. (CTXR) reported revenue of $1.49M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Citius Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Citius Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312022-09-302022-06-302021-09-302021-06-302020-09-302020-06-302019-09-30
Revenue$1.49M$1.67M$3.94M$0Unavailable$0Unavailable$0Unavailable$0
Cost of revenue$491.84K$328.88K$789.21KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profit$1.00M$1.34M$3.15MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$11.73M-$32.19M-$9.02M-$7.55M-$8.92M-$5.20M-$5.98M-$4.14M-$4.69M-$3.66M
Net incomeUnavailableUnavailableUnavailable-$7.99M-$8.86M-$4.96M-$5.82M-$4.12M-$4.68M-$3.65M
Research & development$1.05M$1.63M$1.60M$3.86M$4.89M$2.29M$2.20M$1.49M$2.64M$2.02M
Weighted-average diluted sharesshares 26.17Mshares 22.38Mshares 21.50MUnavailableshares 146.13MUnavailableshares 137.15MUnavailableUnavailableUnavailable
Pretax income-$12.03M-$28.34M-$9.13M-$7.41M-$8.86MUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense-$107.35K-$231.21K$264.24KUnavailableUnavailable-$1$423UnavailableUnavailableUnavailable
Diluted EPS$-0.34$-0.95$-0.38Unavailable$-0.06Unavailable$-0.05UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.15M$26.39M$5.72M$2.72M$3.02M$2.45M$3.41M$2.40M$1.87M$1.50M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Citius Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312022-09-302022-06-302021-09-302021-06-302020-09-302020-06-302019-09-30
Cash & equivalents$17.01M$4.59M$7.72M$41.71M$48.04M$70.07M$115.66M$13.86M$8.52M$7.89M
Total assets$142.26M$132.54M$140.39M$114.00M$120.32M$142.43M$146.59M$43.77M$38.40M$36.75M
Current assets$43.33M$31.69M$37.95M$44.56M$50.83M$72.81M$116.94M$13.98M$8.57M$7.94M
Total liabilities$66.35M$63.46M$46.92M$10.57M$9.98M$9.65M$9.31M$10.10M$9.66M$9.59M
Current liabilities$51.65M$55.02M$38.21M$4.53M$4.46M$3.98M$3.60M$4.10M$3.61M$4.61M
Total equity incl. NCI$75.91M$69.08M$93.47M$103.43M$110.34M$132.78M$137.28M$33.67M$28.74M$27.15M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$22.63M$22.66M$22.64MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$686.24K$1.08M$4.05MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$9.35M$9.35M$9.35M$9.35M$9.35M$9.35M$9.35M$9.35M$9.35M$9.35M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$8.04M$9.45M$11.02M$1.17M$1.69M$1.28M$1.35M$1.86M$1.81M$2.71M

Cash flow

Citius Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312022-09-302022-06-302021-09-302021-06-302020-09-302020-06-302019-09-30
Operating cash flow-$8.68M-$1.30M-$13.01M-$6.33MUnavailable-$5.59MUnavailable-$3.36MUnavailable-$2.91M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable$0Unavailable$0UnavailableUnavailable
Investing cash flow-$2.00M-$600.00K-$4.40MUnavailableUnavailable-$40.00MUnavailable$0UnavailableUnavailable
Financing cash flow$23.09M-$1.23M$20.88MUnavailableUnavailable$0Unavailable$8.70MUnavailable$6.29M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$3.38M
Stock-based compensation$3.81M$3.79M$4.28M$976.68K$1.00M$461.86K$373.57K$249.03K$175.01K$137.04K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Citius Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312022-09-302022-06-302021-09-302021-06-302020-09-302020-06-302019-09-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable-$5.59MUnavailable-$3.36MUnavailableUnavailable
Gross margin67.1%80.3%80.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-785.4%-1931.0%-228.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue255.1%227.2%108.5%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.84x0.58x0.99x9.84x11.40x18.28x32.48x3.41x2.37x1.72x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenue70.6%98.0%40.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CTXR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-K · Filed 2025-12-23View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2019-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2019-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2018-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2018-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.